Nuvation Bio Shares Fall After Disappointing Sales Guidance for Lung-Cancer Treatment

Dow Jones

01/13

By Elias Schisgall

Nuvation Bio shares dipped after the oncology company issued preliminary sales numbers for Ibtrozi behind Wall Street's expectations.

Shares fell 16% to $6.77 late Monday morning. The stock has more than doubled in value in the past year.

The company said Monday that it expects to report net revenue from Ibtrozi, a treatment for non-small cell lung cancer, of $15.7 million in the fourth quarter and $24.7 million since the drug's commercial launch in the second quarter.

Analysts surveyed by FactSet were anticipating $17.1 million in sales for the quarter and $26.1 million since the product launch.

Nuvation said 216 patients had begun Ibtrozi treatment during the fourth quarter, exceeding the company's internal projections. It said that since Ibtrozi's launch, 432 patients have begun taking the treatment, representing a treatment adoption rate about six times greater than that of other similar drug launches, citing data from Iqvia.

The company also said it received a $25 million milestone payment from Nippon Kayaku during the fourth quarter.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 12, 2026 11:26 ET (16:26 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2603542831"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603542831\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603542831?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 00:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603542831","market":"nz","top_or_hot":-1,"title":"Nuvation Bio Shares Fall After Disappointing Sales Guidance for Lung-Cancer Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> shares dipped after the oncology company issued preliminary sales numbers for Ibtrozi behind Wall Street's expectations. \n</p>\n<p>\n  Shares fell 16% to $6.77 late Monday morning. The stock has more than doubled in value in the past year. \n</p>\n<p>\n  The company said Monday that it expects to report net revenue from Ibtrozi, a treatment for non-small cell lung cancer, of $15.7 million in the fourth quarter and $24.7 million since the drug's commercial launch in the second quarter. \n</p>\n<p>\n  Analysts surveyed by FactSet were anticipating $17.1 million in sales for the quarter and $26.1 million since the product launch. \n</p>\n<p>\n  Nuvation said 216 patients had begun Ibtrozi treatment during the fourth quarter, exceeding the company's internal projections. It said that since Ibtrozi's launch, 432 patients have begun taking the treatment, representing a treatment adoption rate about six times greater than that of other similar drug launches, citing data from Iqvia. \n</p>\n<p>\n  The company also said it received a $25 million milestone payment from <a href=\"https://laohu8.com/S/NPKYF\">Nippon Kayaku</a> during the fourth quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 11:26 ET (16:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nuvation Bio Shares Fall After Disappointing Sales Guidance for Lung-Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNuvation Bio Shares Fall After Disappointing Sales Guidance for Lung-Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-13 00:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/NUVB\">Nuvation Bio</a> shares dipped after the oncology company issued preliminary sales numbers for Ibtrozi behind Wall Street's expectations. \n</p>\n<p>\n  Shares fell 16% to $6.77 late Monday morning. The stock has more than doubled in value in the past year. \n</p>\n<p>\n  The company said Monday that it expects to report net revenue from Ibtrozi, a treatment for non-small cell lung cancer, of $15.7 million in the fourth quarter and $24.7 million since the drug's commercial launch in the second quarter. \n</p>\n<p>\n  Analysts surveyed by FactSet were anticipating $17.1 million in sales for the quarter and $26.1 million since the product launch. \n</p>\n<p>\n  Nuvation said 216 patients had begun Ibtrozi treatment during the fourth quarter, exceeding the company's internal projections. It said that since Ibtrozi's launch, 432 patients have begun taking the treatment, representing a treatment adoption rate about six times greater than that of other similar drug launches, citing data from Iqvia. \n</p>\n<p>\n  The company also said it received a $25 million milestone payment from <a href=\"https://laohu8.com/S/NPKYF\">Nippon Kayaku</a> during the fourth quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 11:26 ET (16:26 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603542831","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603542831","pubTimestamp":1768235160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Nuvation Bio shares dipped after the oncology company issued preliminary sales numbers for Ibtrozi behind Wall Street's expectations.Shares fell 16% to $6.77 late Monday morning. The stock has more than doubled in value in the past year.The company said Monday that it expects to report net revenue from Ibtrozi, a treatment for non-small cell lung cancer, of $15.7 million in the fourth quarter and $24.7 million since the drug's commercial launch in the second quarter.Analysts surveyed by FactSet were anticipating $17.1 million in sales for the quarter and $26.1 million since the product launch.Nuvation said 216 patients had begun Ibtrozi treatment during the fourth quarter, exceeding the company's internal projections. It said that since Ibtrozi's launch, 432 patients have begun taking the treatment, representing a treatment adoption rate about six times greater than that of other similar drug launches, citing data from Iqvia.The company also said it received a $25 million milestone pay","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","NUVB":"Nuvation Bio, Inc."},"translate_title":"肺癌治疗销售指引令人失望后，Nuvation Bio股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NUVB":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\nNuvation Bio shares dipped after the oncology company issued preliminary sales numbers for Ibtrozi behind Wall Street's expectations. \n\n\n  Shares fell 16% to $6.77 late Monday morning. The stock has more than doubled in value in the past year. \n\n\n  The company said Monday that it expects to report net revenue from Ibtrozi, a treatment for non-small cell lung cancer, of $15.7 million in the fourth quarter and $24.7 million since the drug's commercial launch in the second quarter. \n\n\n  Analysts surveyed by FactSet were anticipating $17.1 million in sales for the quarter and $26.1 million since the product launch. \n\n\n  Nuvation said 216 patients had begun Ibtrozi treatment during the fourth quarter, exceeding the company's internal projections. It said that since Ibtrozi's launch, 432 patients have begun taking the treatment, representing a treatment adoption rate about six times greater than that of other similar drug launches, citing data from Iqvia. \n\n\n  The company also said it received a $25 million milestone payment from Nippon Kayaku during the fourth quarter. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 11:26 ET (16:26 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}